AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteSplitomicin is a selective NAD(+)-dependent histone deacetylase Sir2p inhibitor with IC50 of 60 ??M, showing a higher activity in a cell-based assay.
More Information Supplier PageSQ109 is an orally active, small molecule antibiotic for treatment of pulmonary T(tuberculosis).
More Information Supplier PageSQ109 is an orally active, small molecule antibiotic for treatment of pulmonary T(tuberculosis).
More Information Supplier PageSQ109 is an orally active, small molecule antibiotic for treatment of pulmonary T(tuberculosis).
More Information Supplier PageSR 11302, inhibitor of activator protein-1 (AP-1) transcription factor activity that displays antitumor effects in vivo.
More Information Supplier PageSR 11302, inhibitor of activator protein-1 (AP-1) transcription factor activity that displays antitumor effects in vivo.
More Information Supplier PageSR 11302, inhibitor of activator protein-1 (AP-1) transcription factor activity that displays antitumor effects in vivo.
More Information Supplier PageSR 144528 is a selective peripheral cannabinoid receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors and a Ki value of 400 nM for rat brain and human recombinant CB1 receptors.
More Information Supplier PageSR 144528 is a selective peripheral cannabinoid receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors and a Ki value of 400 nM for rat brain and human recombinant CB1 receptors.
More Information Supplier PageSR 144528 is a selective peripheral cannabinoid receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors and a Ki value of 400 nM for rat brain and human recombinant CB1 receptors.
More Information Supplier PageSR 144528 is a selective peripheral cannabinoid receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors and a Ki value of 400 nM for rat brain and human recombinant CB1 receptors.
More Information Supplier PageSR 3677 dihydrochloride is a potent and selective Rho-kinase inhibitor (IC50 values are 3 and 56 nM for ROCK-II and ROCK-I respectively).
More Information Supplier PageSR 3677 dihydrochloride is a potent and selective Rho-kinase inhibitor (IC50 values are 3 and 56 nM for ROCK-II and ROCK-I respectively).
More Information Supplier PageSR 3677 dihydrochloride is a potent and selective Rho-kinase inhibitor (IC50 values are 3 and 56 nM for ROCK-II and ROCK-I respectively).
More Information Supplier PageSR 3677 dihydrochloride is a potent and selective Rho-kinase inhibitor (IC50 values are 3 and 56 nM for ROCK-II and ROCK-I respectively).
More Information Supplier PageSR 48692 represents a new, potent, nonpeptide antagonist radioligand of the NT receptor that differentiates between agonist- and antagonist-receptor interactions.
More Information Supplier PageSR 48692 represents a new, potent, nonpeptide antagonist radioligand of the NT receptor that differentiates between agonist- and antagonist-receptor interactions.
More Information Supplier PageSR 48692 represents a new, potent, nonpeptide antagonist radioligand of the NT receptor that differentiates between agonist- and antagonist-receptor interactions.
More Information Supplier PageSR 48692 represents a new, potent, nonpeptide antagonist radioligand of the NT receptor that differentiates between agonist- and antagonist-receptor interactions.
More Information Supplier PageSR-13668 is an Akt inhibitor, is also an orally bioavailable indole-3-carbinol (I3C) analogue inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic and antiangiogenic activities.
More Information Supplier PageSR-13668 is an Akt inhibitor, is also an orally bioavailable indole-3-carbinol (I3C) analogue inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic and antiangiogenic activities.
More Information Supplier PageSR-13668 is an Akt inhibitor, is also an orally bioavailable indole-3-carbinol (I3C) analogue inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic and antiangiogenic activities.
More Information Supplier PageSR-2211 selectively binds RORr(Ki = 105 nM), acting as an inverse agonist of constitutive in vitro RORr activity (IC50 = 320 nM).
More Information Supplier PageSR-2211 selectively binds RORr(Ki = 105 nM), acting as an inverse agonist of constitutive in vitro RORr activity (IC50 = 320 nM).
More Information Supplier PageSR-2211 selectively binds RORr(Ki = 105 nM), acting as an inverse agonist of constitutive in vitro RORr activity (IC50 = 320 nM).
More Information Supplier PageSR1078 is an agonist of retinoic acid receptor-related orphan receptors (ROR) ROR??/??; increases transcription of ROR?? target genes; thought to increase p53 stability.
More Information Supplier PageSR1078 is an agonist of retinoic acid receptor-related orphan receptors (ROR) ROR??/??; increases transcription of ROR?? target genes; thought to increase p53 stability.
More Information Supplier PageSR1078 is an agonist of retinoic acid receptor-related orphan receptors (ROR) ROR??/??; increases transcription of ROR?? target genes; thought to increase p53 stability.
More Information Supplier PageSR3335 is a selective ROR?? synthetic ligand, directly binds to ROR??, but not other RORs, and functions as a selective partial inverse agonist of ROR?? in cell-based assays.
More Information Supplier PageSR3335 is a selective ROR?? synthetic ligand, directly binds to ROR??, but not other RORs, and functions as a selective partial inverse agonist of ROR?? in cell-based assays.
More Information Supplier PageSR3335 is a selective ROR?? synthetic ligand, directly binds to ROR??, but not other RORs, and functions as a selective partial inverse agonist of ROR?? in cell-based assays.
More Information Supplier PageSR9243 is a potent and selective LXR inverse agonist. SR9243 kills cancer cells by inhibiting lipid production and the Warburg effect. It induces cell death in multiple types of cancer and does not cause the side effects that have derailed previous attempts to target these processes.
More Information Supplier PageSR9243 is a potent and selective LXR inverse agonist. SR9243 kills cancer cells by inhibiting lipid production and the Warburg effect. It induces cell death in multiple types of cancer and does not cause the side effects that have derailed previous attempts to target these processes.
More Information Supplier PageSR9243 is a potent and selective LXR inverse agonist. SR9243 kills cancer cells by inhibiting lipid production and the Warburg effect. It induces cell death in multiple types of cancer and does not cause the side effects that have derailed previous attempts to target these processes.
More Information Supplier PageSRPIN340 is a cell-permeable isonicotinamide that acts as an ATP-competitive SRPK1-selective inhibitor (IC50 = 0.14 and 1.8 ??M, respectively, against mSRPK1 and mSRPK2) with much reduced activity against 143 other kinases.
More Information Supplier PageSRPIN340 is a cell-permeable isonicotinamide that acts as an ATP-competitive SRPK1-selective inhibitor (IC50 = 0.14 and 1.8 ??M, respectively, against mSRPK1 and mSRPK2) with much reduced activity against 143 other kinases.
More Information Supplier PageSRPIN340 is a cell-permeable isonicotinamide that acts as an ATP-competitive SRPK1-selective inhibitor (IC50 = 0.14 and 1.8 ??M, respectively, against mSRPK1 and mSRPK2) with much reduced activity against 143 other kinases.
More Information Supplier PageSRPIN340 is a cell-permeable isonicotinamide that acts as an ATP-competitive SRPK1-selective inhibitor (IC50 = 0.14 and 1.8 ??M, respectively, against mSRPK1 and mSRPK2) with much reduced activity against 143 other kinases.
More Information Supplier PageSRT 1720 is a selective activator of human SIRT1 (EC1.5 = 0.16 ??M) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 uM??SIRT3: EC1.5 > 300 uM).
More Information Supplier PageSRT 1720 is a selective activator of human SIRT1 (EC1.5 = 0.16 ??M) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 uM??SIRT3: EC1.5 > 300 uM).
More Information Supplier PageSRT 1720 is a selective activator of human SIRT1 (EC1.5 = 0.16 ??M) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 uM??SIRT3: EC1.5 > 300 uM).
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier PageSRT3109 is a CXCR2 ligand for use in the treatment of chemokine mediated diseases and conditions.
More Information Supplier Page
